A SINGLE-CENTER OBSERVATIONAL LONGITUDINAL STUDY ON THE EFFECT OF SLOW WAVE SLEEP (SWS) CHARACTERISTICS AND RACE AND ETHNICITY ON AMYLOID BURDEN (A MARKER OF ALZHEIMER S DISEASE RISK) AMONG COGNITIVELY NORMAL ELDERLY.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alzheimer's Disease
  • Age: Between 55 - 75 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Within normal limits on neurological and psychiatric examinations. All subjects enrolled will have both a CDR=0, a Mini–Mental State Examination (MMSE)259>26 and =-1.25 in global cognition z-scores from the WHICAP battery.
    2. An informed family member or life-partner (preferably bed-partner) will be interviewed to confirm the reliability of the subject interview.
    3. Self-identified as African-American Black or non-Hispanic white.

You may not be eligible for this study if the following are true:

    1. History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson’s disease or other movement disorders). Subjects with a Fazekas scale >2 will be excluded
    2. Significant history of alcoholism or drug abuse.
    3. History of psychiatric illness (e.g., schizophrenia, bipolar or PTSD
    4. Lifelong depression and anxiety will be allowed as long as there has been no active depressive episode within the last two years.
    5. Geriatric Depression Scale212 (short form)>5.
    6. Insulin dependent diabetes.
    7. Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
    8. Physical impairment of such severity as to adversely affect the validity of psychological testing.
    9. Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
    10. Medications affecting cognition or SWS: oNarcotic analgesics. oChronic use of medications with anticholinergic activity. oAnti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline). oOthers: amphetamines, amphetamine-like compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine, disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants, gabapentin, pregabalin, trazodone, salicylates, cholinesterase inhibitors, memantine.
    11. History of a first-degree family member with early onset (age <60 years) dementia.
    12. Irregular sleep-wake rhythms (based on the actigraphy recordings), short sleepers (< 5 hours a day) and long sleepers (> 9 hours a day).
    13. OSA (defined as AHI4%>15 and AHI4%>5 with Epworth=10)
    14. Self-identified as US-born Caribbean Black, Caribbean-born Black or African-born Black.



If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.